Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 11, 2011, Pages 1515-1521

  Kabali, Conrad ^a   Von Reyn, C F ^b   Brooks, D R ^c   Waddell, R ^b   Mtei, L ^d   Bakari, M ^d   Matee, M ^d   Pallangyo, K ^d   Arbeit, R D ^e   Horsburgh Jr , C R ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Isoniazid; Survival; Tuberculosis

Indexed keywords

ISONIAZID; TUBERCULIN;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SURVIVAL RATE; TANZANIA; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; ISONIAZID; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TANZANIA; TIME FACTORS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS VACCINES; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 80053987141     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0788     Document Type: Article

References (27)

1. Raviglione M C, Narain J P, Kochi A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis and treatment. Bull World Health Organ 1992; 70: 515-526.
2. Raviglione M C, Snider D E, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-226.
3. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst Rev 2010; (1): CD000171.
4. World Health Organization Global Tuberculosis Programme, Joint United Nations Programme on HIV/AIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV. WHO/TB/98.255. Geneva, Switzerland: WHO, 1998. http://www.who.int/docstore/gtb/publications/TB-HIV-polstmnt/index.html Accessed August 2011.
5. Date A A, Victoria M, Granich R, Banda M, Fox M Y, Gilks C. Implementation of cotrimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ 2010; 88: 253-259.
6. Golub J E, Saraceni V, Cavalcante S C, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on t uberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21: 1441-1448. (Pubitemid 46988004)
7. Getahun H, Van Gorkom J, Harries A, et al. Interim policy on collaborative TB/HIV activities. Geneva, Switzerland: Stop TB Department and Department of HIV/AIDS, WHO, 2004.
8. Johnson J L, Okwera A, Hom D L, et al. Duration of effi cacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15: 2137-2147. (Pubitemid 33101821)
9. Quigley M A, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15: 215-222. (Pubitemid 32142297)
10. Munseri P J, Talbot E A, Mtei L, Fordham von Reyn C. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis 2008; 12: 1037-1041.
11. Wilkinson D. Drugs for preventing tuberculosis in HIV-infected persons. Cochrane Database Syst Rev 2000; (4): CD000171.
12. Snider D E Jr, Caras G J, Koplan J P. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986; 255: 1579-1583. (Pubitemid 16167478)
13. Pape J W, Jean S S, Ho J L, Hafner A, Johnson W D Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-272. (Pubitemid 23224420)
14. Fitzgerald D W, Desvarieux M, Severe P, Joseph P, Johnson W D Jr, Pape J W. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1 infected individuals: a randomized trial. Lancet 2000; 356: 1470-1474.
15. Casado J L, Moreno S, Fortun A, et al. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodefi ciency virus-infected patients. Clin Infect Dis 2002; 34: 386-389. (Pubitemid 34062241)
16. World Health Organization Stop TB Department, Department of HIV/AIDS. Guidelines for intensified tuberculosis casefi nding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/publications/2011/978 9241500708-eng.pdf Accessed August 2011.
17. von Reyn C F, Mtei L, Arbeit R D, et al. Prevention of tuberculosis in bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24: 675-685.
18. Floyd S, Ponnighaus J M, Bliss L, et al. BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size. Int J Tuberc Lung Dis 2000; 12: 1133-1142. (Pubitemid 32046291)
19. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40: 1500-1507. (Pubitemid 40628639)
20. Matee M, Mtei L, Lounasvaara T, et al. Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. BMC Public Health 2008; 8: 68.
21. National AIDS Control Programme. National guidelines for the management of HIV and AIDS. 3rd ed. Dar es Salaam, Tanzania: NACP, 2008.
22. Charalambous S, Grant A D, Innes C, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010; 24 (Suppl 5): S5-S13.
23. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1986; 79: 340-349.
24. Zar H J, Cotton M F, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007; 334: 336.
25. Wilkinson D, Squire S B, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomized placebo controlled trials. BMJ 1998; 317: 625-629. (Pubitemid 28403484)
26. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564.
27. Reid A, Scano F, Getahun H, et al. Towards universal access to HIV prevention, treatment, care and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis 2006; 6: 483-495. (Pubitemid 44109811)